Choose the most applicable biomarkers according to specific cancer indications and custom requirements for your targeted therapies with QIAGEN Real-World Insights (RWI)
Deciding which biomarkers to include and what technology to use is neither simple nor straight forward. Clinical relevance, reliability, and practicality are of critical importance when selecting biomarkers.
Using robust genomic sequencing data and molecular testing trends, QIAGEN RWI analyses can identify, prioritize and validate biomarkers of therapeutic response and resistance to optimize your drug development strategy.
Oncology development is increasingly personalized and precise, with narrower and more nuanced indications characterized by genomic alterations. QIAGEN RWI provides information beyond the prevalence of a biomarker for a drug to answer more meaningful questions, such as:
QIAGEN’s RWI portfolio combines real-world genomic data from over 200,000 cancer cases and advanced analytics to achieve Better Decisions Faster™ in early drug and biomarker development.
To access RWI, you can:
Do you have novel questions, hypotheses, and hurdles to overcome? Our team of scientists, bioinformaticists, and clinicians can help you strategize, customize, and deliver within your timeline.
Identify appropriate patient cohorts and enhance your CDx design to improve stratification and success
More easily find the right patients and quickly move to recruitment and regulatory acceptance
Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses